VOICE Trial Results and Implications for Future ResearchMarch 11, 2013
Results from the three-arm HIV prevention trial VOICE – Vaginal and Oral Interventions to Control the Epidemic – were recently presented at the 20th Conference on Retroviruses and Opportunistic Infections. The data showed that none of three interventions tested—daily oral tenofovir, daily oral TDF/FTC (Truvada), and daily 1% vaginal tenofovir gel—provided additional protection against HIV in this study, likely because few of the women in the trial used the products as directed.
This global advocates’ webinar included a presentation of the data from VOICE co-principal investigator Jeanne Marrazzo followed by a moderated discussion, which included clarifying questions around the trial itself as well as discussion of the implications these results have for ongoing and planned HIV prevention research and implementation.
Written summary: PDF